

# Autoimmune IV Enrollment Form



Fax Referral To: 1-877-232-5455  
Address: 500 Ala Moana Blvd., Bldg 1 Honolulu, HI 96813

Phone: 1-808-254-2727  
NCPDP: 1203417

## Six Simple Steps to Submitting a Referral

### 1 PATIENT INFORMATION *(Complete or include demographic sheet)*

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Gender:  Male  Female

Address: \_\_\_\_\_ City, State, ZIP Code: \_\_\_\_\_

Preferred Contact Methods:  Phone (to primary # provided below)  Text (to cell # provided below)  Email (to email provided below)

*Note: Carrier charges may apply. By providing the phone number(s) and email address above, you are consenting to receive automated calls, emails and/or text messages from CVS Specialty® about your prescription(s), account, and health care. Standard data rates apply. Message frequency varies. If unable to contact via text or email, Specialty Pharmacy will attempt to contact by phone.*

Primary Phone: \_\_\_\_\_ Alternate Phone: \_\_\_\_\_

Email: \_\_\_\_\_ Last Four of SSN: \_\_\_\_\_ Primary Language: \_\_\_\_\_

Parent/Caregiver/Legal Guardian Name (Last, First): \_\_\_\_\_ Relationship to patient: \_\_\_\_\_

### 2 PRESCRIBER INFORMATION

Prescriber's Name: \_\_\_\_\_ State License #: \_\_\_\_\_

NPI #: \_\_\_\_\_ DEA #: \_\_\_\_\_ Group or Hospital: \_\_\_\_\_

Address: \_\_\_\_\_ City, State, ZIP Code: \_\_\_\_\_

Phone: \_\_\_\_\_ Fax: \_\_\_\_\_ Contact Person: \_\_\_\_\_ Contact's Phone: \_\_\_\_\_

### 3 INSURANCE INFORMATION Please fax copy of prescription and insurance cards with this form, if available (front and back)

### 4 DIAGNOSIS AND CLINICAL INFORMATION

Needs by Date: \_\_\_\_\_ Ship to:  Patient  Office  Other: \_\_\_\_\_

**Diagnosis (ICD-10):**  Date of Diagnosis \_\_\_/\_\_\_/\_\_\_

K50.00 Crohn's Disease of Small Intestine Without Complications

K51.90 Ulcerative colitis, unspecified, without complications

L40.50 Arthropathic Psoriasis, Unspecified

L40.54 Juvenile Psoriatic Arthritis (JPsA)

M06.9 Rheumatoid Arthritis, Unspecified

M08.00 Juvenile Idiopathic Arthritis (JIA)

M32.1 Systemic lupus erythematosus (SLE)

M32.14 Glomerular disease in systemic lupus erythematosus

M45.9 Ankylosing Spondylitis of Unspecified Sites in Spine

M45.A0 Non-Radiographic Axial Spondylarthritis (nr-axSpA)

Other Code: \_\_\_\_\_ Description: \_\_\_\_\_

#### **Patient Clinical Information:**

Allergies: \_\_\_\_\_  NKDA Weight: \_\_\_\_\_  kg  lb Height: \_\_\_\_\_  cm  in

Treatment status:  New to therapy  Continuation of therapy; Date of last treatment \_\_\_/\_\_\_/\_\_\_

TB Test Date \_\_\_/\_\_\_/\_\_\_  Positive  Negative  Hepatitis status: \_\_\_\_\_

Prior therapy, treatment dates, and reason(s) for discontinuation: \_\_\_\_\_

#### **Nursing and Administration:**

First dose administration of monoclonal antibodies (mABs) should be administered in a controlled setting (may vary depending upon medication specific policy).

**For Remicade/Remicade Biosimilars, the first dose must be administered in a controlled setting.**

Specialty pharmacy to coordinate home health Infusion nurse visit as necessary?  Yes  No

Site of Care:  Home Infusion\*  Coram Ambulatory Infusion Suite (AIS)\*  Prescriber's Office\*\*  Other Infusion Clinic

\*Home Infusion/Coram AIS: Diluents, Flushes, Supplies, Nursing Services for drug administration/therapy teach train.

\*\*Prescriber's Office/Other Infusion Clinic: Drug only for facility administration

# Autoimmune IV Enrollment Form

## Please Complete Patient and Prescriber Information

Patient Name: \_\_\_\_\_ Patient DOB: \_\_\_\_\_ Patient Phone: \_\_\_\_\_  
 Prescriber Name: \_\_\_\_\_ Prescriber Phone: \_\_\_\_\_

### Patient Clinical Information:

Allergies: \_\_\_\_\_  NKDA      Weight: \_\_\_\_\_  kg  lb      Height: \_\_\_\_\_  cm  in  
 Treatment status:  New to therapy       Continuation of therapy; Date of last treatment \_\_\_/\_\_\_/\_\_\_  
 TB Test Date \_\_\_/\_\_\_/\_\_\_  Positive  Negative       Hepatitis status: \_\_\_\_\_  
 Prior therapy, treatment dates, and reason(s) for discontinuation: \_\_\_\_\_

## 5 PRESCRIPTION INFORMATION

MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
<input type="checkbox"/> Actemra	<input type="checkbox"/> 80 mg/4 mL <input type="checkbox"/> 200 mg/10 mL <input type="checkbox"/> 400 mg/20 mL	<input type="checkbox"/> Induction Dose: Infuse 4 mg/kg every 4 weeks <input type="checkbox"/> Maintenance Dose: Infuse 8 mg/kg every 4 weeks	Quantity: _____ Refills: _____
<input type="checkbox"/> Avsola	100 mg vial	<input type="checkbox"/> Ankylosing Spondylitis Induction Dose: Infuse IV at 5 mg/kg (Dose = _____mg) at weeks 0, 2, 6 and every 6 weeks thereafter <input type="checkbox"/> Ankylosing Spondylitis Maintenance Dose: Infuse IV at 5 mg/kg (Dose = _____mg) every 6 weeks <input type="checkbox"/> Crohn's Disease (Adult and Pediatric ≥ 6 years old) Induction Dose: Infuse IV at 5 mg/kg (Dose = _____mg) at weeks 0, 2, 6 and every 8 weeks thereafter <input type="checkbox"/> Crohn's Disease (Adult) Maintenance Dose: Infuse IV at 5-10 mg/kg (Dose = _____mg) every 8 weeks <input type="checkbox"/> Crohn's Disease (Pediatric ≥ 6 years old) Maintenance Dose: Infuse IV at 5 mg/kg (Dose = _____mg) every 8 weeks <input type="checkbox"/> Plaque Psoriasis & Psoriatic Arthritis Induction Dose: Infuse IV at 5 mg/kg (Dose = _____mg) at weeks 0, 2, 6 and every 8 weeks thereafter <input type="checkbox"/> Plaque Psoriasis & Psoriatic Arthritis Maintenance Dose: Infuse IV at 5 mg/kg (Dose = _____mg) every 8 weeks <input type="checkbox"/> Rheumatoid Arthritis Induction Dose: Infuse IV at 3 mg/kg (Dose = _____mg) at weeks 0, 2, 6 and every 8 weeks thereafter <input type="checkbox"/> Rheumatoid Arthritis Maintenance Dose: Infuse IV at 3-10 mg/kg (Dose = _____mg) every 4, 6 or 8 weeks (circle one) <input type="checkbox"/> Ulcerative Colitis (Adult and Pediatric ≥ 6 years old) Induction Dose: Infuse IV at 5 mg/kg (Dose = _____mg) at weeks 0, 2, 6 and every 8 weeks thereafter <input type="checkbox"/> Ulcerative Colitis (Adult and Pediatric ≥ 6 years old) Maintenance Dose: Infuse IV at 5 mg/kg (Dose = _____mg) every 8 weeks	Quantity: _____ # of 100 mg vial(s) Refills: _____
<input type="checkbox"/> Benlysta	<input type="checkbox"/> 120 mg 5 mL vial <input type="checkbox"/> 400 mg 20 mL vial	<input type="checkbox"/> Induction Dose: 10 mg/kg IV (Dose = _____mg) at 2-week intervals for the first 3 doses and at 4-week intervals thereafter. Infuse IV over 1 hour.	Quantity: _____ vials Refills: _____
<input type="checkbox"/> Cosentyx	125 mg/5 mL vial	<u>Loading Dose:</u> <input type="checkbox"/> Infuse 6 mg/kg (Dose = _____ mg) at Week 0	Quantity: _____ Refills: 0
		<u>Maintenance Dose:</u> <input type="checkbox"/> Infuse 1.75 mg/kg (Dose = _____ mg) every 4 weeks (max. maintenance dose: 300 mg per infusion)	Quantity: _____ Refills: _____
<input type="checkbox"/> Entyvio	300 mg in a single dose vial in individual carton	<input type="checkbox"/> Induction Dose: 300 mg infused IV over 30 minutes at 0, 2 and 6 weeks, then every 8 weeks thereafter <input type="checkbox"/> Maintenance Dose: 300 mg infused IV over 30 minutes every 8 weeks	Quantity: _____ Refills: _____
<input type="checkbox"/> Other	<input type="checkbox"/> Strength: _____	<input type="checkbox"/> Dose: _____	Quantity: _____ Refills: _____

## 6 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute <b>Prescriber's Signature:</b> _____ <b>Date:</b> _____	May Substitute / Product Selection Permitted / Substitution Permissible <b>Prescriber's Signature:</b> _____ <b>Date:</b> _____
<b>CA, MA, NC &amp; PR:</b> Interchange is mandated unless Prescriber writes the words "No Substitution" <b>ATTN: New York and Iowa providers,</b> please submit electronic prescription	

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.



# Autoimmune IV Enrollment Form

## Please Complete Patient and Prescriber Information

Patient Name: \_\_\_\_\_ Patient DOB: \_\_\_\_\_ Patient Phone: \_\_\_\_\_

Prescriber Name: \_\_\_\_\_ Prescriber Phone: \_\_\_\_\_

### Patient Clinical Information:

Allergies: \_\_\_\_\_  NKDA Weight: \_\_\_\_\_  kg  lb Height: \_\_\_\_\_  cm  in

Treatment status:  New to therapy  Continuation of therapy; Date of last treatment \_\_\_/\_\_\_/\_\_\_

TB Test Date \_\_\_/\_\_\_/\_\_\_  Positive  Negative  Hepatitis status: \_\_\_\_\_

Prior therapy, treatment dates, and reason(s) for discontinuation: \_\_\_\_\_

### 5 PRESCRIPTION INFORMATION

MEDICATION	STRENGTH	DOSE & DIRECTIONS	QUANTITY/REFILLS
<input type="checkbox"/> Riabni <input type="checkbox"/> Rituxan <input type="checkbox"/> Ruxience	<input type="checkbox"/> 100 mg/10 mL vial <input type="checkbox"/> 500 mg/50 mL vial	<input type="checkbox"/> Infuse two doses of 1000 mg separated by 2 weeks	Quantity: _____ Refills: _____
<input type="checkbox"/> Saphnelo	300 mg/2 mL (150 mg/mL)	<input type="checkbox"/> 300 mg IV over a 30-minute period, every 4 weeks	Quantity: _____ vials Refills: _____
<input type="checkbox"/> Simponi ARIA	50 mg/4 mL single dose vial	<b>Adult RA, PsA, AS Induction Dose</b> <input type="checkbox"/> Week 0: Infuse 2 mg/kg IV (Dose= _____ mg) over 30 minutes <input type="checkbox"/> Week 4: Infuse 2 mg/kg IV (Dose= _____ mg) over 30 minutes	Quantity: _____ vials Refills: _____ 0 _____ Quantity: _____ vials Refills: _____ 0 _____
		<b>Adult RA, PsA, AS Maintenance Dose</b> <input type="checkbox"/> Infuse 2 mg/kg IV (Dose= _____ mg) over 30 minutes every 8 weeks	Quantity: _____ vials Refills: _____
		<b>Peds JIA or PsA (&gt;2 years old) Induction Dose</b> <input type="checkbox"/> Week 0: Infuse 80 mg/m <sup>2</sup> IV (Dose= _____ mg) over 30 minutes <input type="checkbox"/> Week 4: Infuse 80 mg/m <sup>2</sup> IV (Dose= _____ mg) over 30 minutes	Quantity: _____ vials Refills: _____ 0 _____ Quantity: _____ vials Refills: _____ 0 _____
		<b>Peds JIA or PsA (&gt;2 years old) Maintenance Dose</b> <input type="checkbox"/> Infuse 80 mg/m <sup>2</sup> IV (Dose= _____ mg) over 30 minutes every 8 weeks	Quantity: _____ vials Refills: _____
<input type="checkbox"/> Skyrizi	<input type="checkbox"/> 600 mg/10 mL (60 mg/mL) single dose vial	<b>Induction Dose:</b> <input type="checkbox"/> Week 0: Infuse 600 mg IV over at least one hour <input type="checkbox"/> Week 4: Infuse 600 mg IV over at least one hour <input type="checkbox"/> Week 8: Infuse 600 mg IV over at least one hour	Quantity: <input type="checkbox"/> 2 Vials <input type="checkbox"/> 3 Vials <input type="checkbox"/> 4 Vials Refills: 0
<input type="checkbox"/> Stelara	130 mg/26 mL (5 mg/mL) IV single-dose vial	<b>Single IV Induction Dose:</b> <input type="checkbox"/> 55 kg or less 260 mg at week 0: # of vials to be used 2 <input type="checkbox"/> more than 55 kg to 85 kg 390 mg at week 0: # of vials to be used 3 <input type="checkbox"/> more than 85 kg 520 mg at week 0: # of vials to be used 4	Quantity: <input type="checkbox"/> 2 Vials <input type="checkbox"/> 3 Vials <input type="checkbox"/> 4 Vials Refills: 0
<input type="checkbox"/> Truxima	<input type="checkbox"/> 100 mg/10 mL vial <input type="checkbox"/> 500 mg/50 mL vial	<input type="checkbox"/> Infuse two doses of 1000 mg separated by 2 weeks	Quantity: _____ Refills: _____
<input type="checkbox"/> Other	<input type="checkbox"/> Strength: _____	<input type="checkbox"/> Dose: _____	Quantity: _____ Refills: _____

### 6 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)

"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute <b>Prescriber's Signature:</b> _____ <b>Date:</b> _____	May Substitute / Product Selection Permitted / Substitution Permissible <b>Prescriber's Signature:</b> _____ <b>Date:</b> _____
<b>CA, MA, NC &amp; PR:</b> Interchange is mandated unless Prescriber writes the words "No Substitution" <b>ATTN: New York and Iowa providers,</b> please submit electronic prescription	

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

# Autoimmune IV Enrollment Form

## Nursing Orders

### Please Complete Patient and Prescriber Information

Patient Name: \_\_\_\_\_ Patient DOB: \_\_\_\_\_ Patient Phone: \_\_\_\_\_  
 Prescriber Name: \_\_\_\_\_ Prescriber Phone: \_\_\_\_\_

**Patient Clinical Information:**

Allergies: \_\_\_\_\_  NKDA Weight: \_\_\_\_\_  kg  lb Height: \_\_\_\_\_  cm  in  
 Treatment status:  New to therapy  Continuation of therapy; Date of last treatment \_\_\_/\_\_\_/\_\_\_  
 TB Test Date \_\_\_/\_\_\_/\_\_\_  Positive  Negative  Hepatitis status: \_\_\_\_\_  
 Prior therapy, treatment dates, and reason(s) for discontinuation: \_\_\_\_\_

**5 PRESCRIPTION INFORMATION \*\*ITEMS BELOW THIS LINE WILL ONLY BE SENT FOR INFUSIONS DONE AT HOME/CORAM AIS\*\***

MEDICATION/SUPPLIES	ROUTE	DOSE /STRENGTH/ DIRECTIONS	QUANTITY/REFILLS
Catheter: <input type="checkbox"/> PIV <input type="checkbox"/> PORT <input type="checkbox"/> CVC/PICC	IV	Catheter Care/Flush – Only on drug admin days – SASH or PRN to maintain IV access and patency PIV: NS 5 mL (Heparin 10 units/mL 3-5 mL if multiple days) CVC/PICC: NS 10 mL & <input type="checkbox"/> Heparin 10 units/mL or <input type="checkbox"/> 100 units/mL 3-5 mL. PORT: 10 mL sterile saline to access PORT w/ huber needle NS 10 mL & Heparin 100 units/mL 3-5mL.	Quantity: _____ Refills: _____
Hydration: <input type="checkbox"/> NS <input type="checkbox"/> D5W	IV	Pre: <input type="checkbox"/> 500 mL <input type="checkbox"/> 1000 mL <input type="checkbox"/> Other: _____ Concurrent: <input type="checkbox"/> 500 mL <input type="checkbox"/> 1000 mL <input type="checkbox"/> Other: _____ Post: <input type="checkbox"/> 500 mL <input type="checkbox"/> 1000 mL <input type="checkbox"/> Other: _____	Hydration max infusion rate _____ mL/hr (Adult max rate 250 mL/hr unless otherwise indicated)
<input type="checkbox"/> Epinephrine <i>**nursing requires**</i>	<input type="checkbox"/> IM <input type="checkbox"/> SC	<input type="checkbox"/> 1:1000, 0.3mg/0.3 mL (greater than 30 kg/66 lbs) <input type="checkbox"/> 1:1000, 0.15mg/0.3 mL (15-30 kg/33-66 lbs) <input type="checkbox"/> 1:1000, 0.1 mg/kg, Max 0.3mg (under 15kg) Mild-Moderate Reactions. May repeat in 3-5 minutes as needed for severe allergic reaction, also call 911	Quantity: _____ Refills: _____
<input type="checkbox"/> Diphenhydramine Oral	PO	Premedication: <input type="checkbox"/> 12.5 mg/kg (0-30 kg) <input type="checkbox"/> 25 mg <input type="checkbox"/> 50 mg (Over 30 kg)	Quantity: _____ Refills: _____
<input type="checkbox"/> Diphenhydramine 50 mg/mL vial <i>**nursing required**</i>	<input type="checkbox"/> Slow IV <input type="checkbox"/> IM	<input type="checkbox"/> 1 mg/kg (under 15 kg) <input type="checkbox"/> 12.5 mg-50 mg (15-30 kg) <input type="checkbox"/> 25 mg-50 mg (Over 30 kg) If mild/moderate reaction: may repeat in 3-5 minutes as needed (Adult max dose: 100 mg/day) If severe allergic reaction: call 911	Quantity: _____ Refills: _____
<input type="checkbox"/> Flush Orders:	<input type="checkbox"/> Peripheral Access <input type="checkbox"/> Central Venous Access	<input type="checkbox"/> 10 mL NS post flush <input type="checkbox"/> 50 mL NS post flush to clear medication from tubing (recommended if no post-hydration) <input type="checkbox"/> Other: _____	Send quantity sufficient for medication days supply
<input type="checkbox"/> Additional Medication:	_____	_____	_____

Patient is interested in patient support programs **STAMP SIGNATURE NOT ALLOWED** Ancillary supplies and kits provided as needed for administration

**3 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)**

"Dispense As Written" / Brand Medically Necessary / Do Not Substitute / No Substitution / DAW / May Not Substitute <b>Prescriber's Signature:</b> _____ <b>Date:</b> _____	May Substitute / Product Selection Permitted / Substitution Permissible <b>Prescriber's Signature:</b> _____ <b>Date:</b> _____
<b>CA, MA, NC &amp; PR:</b> Interchange is mandated unless Prescriber writes the words "No Substitution" <span style="float: right;"><b>ATTN: New York and Iowa providers,</b> please submit electronic prescription</span>	

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

**CONFIDENTIALITY NOTICE:** This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.